Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial – PubMed

One of the things I prefer about CAR-T is the prolonged break patients get from continuous treatment. A small survey (subject to many severe biases with low completion rate/attrition) shows that patients prefer this too.

Read the full article here

Related Articles